HARRISBURG, Pa. (AP) — Pennsylvania’s Supreme Court ruled Tuesday that the state police can’t hide from the public its policy on how it monitors social media.
Advocates for civil liberties cheered the decision. The law enforcement agency had argued that fully disclosing its policy for using software to monitor online postings may compromise public safety.
All four Democratic justices supported the majority decision, which said the lower Commonwealth Court went beyond its authority in trying to give the state police another attempt to justify keeping details of the policy a secret. Tuesday’s order appears to end a six-year legal battle.
A state police spokesperson said the agency is reviewing the court decision.
HARRISBURG, Pa. (AP) — A legal challenge in Pennsylvania over the viability of a particular manufacturer’s voting system has ended in a settlement that advocates say will boost accountability and transparency by requiring election officials to record and publicly report problems with voting machines.
The election-security advocates who sued say such a requirement will provide a contemporary account of which voting machines are working well and which ones aren’t — information that can benefit every state.
Some election officials also see the potential to help suppress conspiracy theories and misinformation about voting machine malfunctions that can fester on Election Day and in the days after when votes are being counted.
Others worry, though, about the breadth of what must be reported and if it could be used to undermine confidence in elections.
PITTSBURGH – Trib-Live reports…A newly approved vaccine for respiratory syncytial virus, better known as RSV, will give pregnant moms a chance to protect their babies from wheezing, coughing and other more serious symptoms that can land infants in the hospital.
Pfizer Inc.’s Abrysvo is the first vaccine for use during pregnancy that works to prevent lower respiratory tract disease caused by RSV in babies from birth through 6 months of age. It was approved Monday by the U.S. Food and Drug Administration.
The vaccine next will need to receive specific Centers for Disease Control clinical guidance on how to use it most effectively. The single-dose injection also was approved earlier this year for adults over 60, as older adults and young children are most at-risk of severe disease from RSV.
